Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II

Inclusion Criteria: 1. Provision of written informed consent, with full understanding of and agreement to comply with study requirements and the visit schedule. 2. Age 18-75 years (inclusive) at the time of informed consent; either sex. 3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 4. Histologically or cytologically confirmed stage III-IVB squamous cell carcinoma of the head and neck as assessed by the investigator. 5. Documented EGFR-positive tumor. 6. No prior systemic therapy for head and neck squamous cell carcinoma. 7. At least one measurable lesion per RECIST v1.1. 8. Estimated life expectancy ≥ 12 weeks. 9. Adequate bone-marrow and organ function. Exclusion Criteria: 1. Known hypersensitivity to any component of PD(L)-1 inhibitors, paclitaxel, or cisplatin. 2. Prior or concurrent malignancy (except adequately treated basal-cell carcinoma, cervical carcinoma in situ, or papillary thyroid carcinoma disease-free for \>5 years). 3. Uncontrolled cardiac symptoms or clinically significant cardiac disease. 4. Previous therapy with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies, or receipt of therapeutic cancer vaccines or live vaccines within 4 weeks before first study-dose administration. 5. Failure to recover to ≤ Grade 1 (per CTCAE) from prior anti-tumour therapy-except alopecia or residual neurotoxicity related to prior platinum-before first study dose. 6. Severe infection (\> CTCAE Grade 2) within 4 weeks before first study dose. 7. Active autoimmune disease or documented autoimmune-disease history requiring systemic therapy. 8. History of immunodeficiency, including positive HIV test, congenital or acquired immunodeficiency syndromes, or prior solid-organ or allogeneic bone-marrow transplantation. 9. History of interstitial lung disease or non-infectious pneumonitis. 10. Evidence of active tuberculosis infection on history or CT imaging. 11. Active hepatitis B (HBV DNA ≥ 500 IU/mL or ≥ 2,500 copies/mL). 12. History of substance abuse, alcohol abuse, or drug addiction. 13. Pregnant or lactating women. 14. Any condition that, in the investigator's opinion, could necessitate premature withdrawal from the study.